1 active not recruiting, 1 completed, 1 not yet recruiting, 1 unknown. 2 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Pantothenic Acid: new trials by email Literature Review of Pantothenic Acid trials Research Report on Pantothenic Acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash, La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream, La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) - Cancer | Not applicable | Not yet recruiting | Stanford University | 50 | 2026-10-01 | 2026-09-11 |
| A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma C-PAN, Nivolumab, Ipilimumab - Melanoma (Skin) | Phase 1 | Active not recruiting | University Health Network, Toronto | 12 | 2024-06-24 | 2026-06-08 |
| Clinical Study of Vitamin B5 in Adjuvant Treatment of IBD Vitamin B5 Tablets, placebo - Inflammatory Bowel Diseases | Not applicable | Unknown | Changhai Hospital | 100 | 2023-02-01 | 2023-06-15 |
| A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine). Corticosteroids, Placebo, capecitabine [Xeloda] - Breast Cancer | Phase 3 | Completed | Hoffmann-La Roche | 598 | 2008-12-01 | 2016-11-02 |
Breast Neoplasms (1) · Inflammatory Bowel Diseases (1) · Melanoma (1) · Neoplasms (1) · Skin Neoplasms (1)
Changhai Hospital (1) · Hoffmann-La Roche (1) · Stanford University (1) · University Health Network, Toronto (1)
Brazil (1) · Canada (1) · China (1) · United States (1)
Lisa Zaba, MD, PhD (1) · Samuel Saibil (1) · Shu Zhu, PhD (1) · Zhaoshen Li, MD (1)